Figure 3.

MEFT80D, but not MEFT80A enhances skeletal myogenesis. (A) P19[Control], P19[MEF2C], P19[MEFT80A], and P19[MEFT80D] stable cell lines were differentiated and examined by immunofluorescence with an anti-MHC antibody, MF20, to detect skeletal muscle, and counter stained with Hoechst dye to visualize the nuclei (× 400). (B) Skeletal myocytes and total nuclei for 10 random fields from different clones were counted and shown as a percentage of total cells, ±s.e.m. (n=3). (C) Western blot analysis of total protein extracts with anti-flag antibodies, showed similar levels of exogenous wild-type and mutant MEF2C protein. (D) Q–PCR analysis from RNA harvested on day 6 or 9 was performed with the genes indicated. Results were normalized to β-actin, and expressed as normalized fold-change relative to P19[Control] cells (n=15). ^*P<0.05.